

Details of Q4 FY24 Quarterly Report, Appendix 4C & Webinar

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) advises that it will release its Q4 FY24 Quarterly Activities Report, Appendix 4C and Quarterly Investor Presentation at 9:00am AEST on Thursday, 25 July 2024.

The Company will also release a Quarterly Investor Presentation Webinar with **CEO Dr Luke Reid** and **SVP, Therapeutics Prof. Trent Munro** presenting at 9:00am AEST on Thursday, 25 July 2024.

Quarterly Investor Presentation Webinar

Presenting: CEO, Dr Luke Reid and SVP, Therapeutics Prof. Trent Munro

Release Time & Date: 9:00am AEST on Thursday, 25 July 2024

Webinar Access: The Quarterly Investor Presentation Webinar can be accessed via Microba’s Investor Hub at the following link on Thursday, 25 July 2024 at 9:00am: <https://ir.microba.com/link/aP3zxr>

Investor Q&As

We invite investors and interested parties to submit questions prior to the Quarterly Investor Presentation Webinar through the ‘Ask a question’ section of Microba’s interactive investor platform by following this link:

<https://ir.microba.com/link/7eXR2P>

Microba’s Investor Hub

To be notified when the Q4 FY24 Quarterly Report, Appendix 4C, Investor Presentation & Webinar as well as other announcements are released, please sign up to Microba’s Investor Hub by following the instructions below.

1. Visit <https://ir.microba.com/welcome>
2. Follow the prompts to sign up for an account.
3. Complete your account profile.

This announcement has been authorised for release by the Chair and CEO.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

luke.reid@microba.com

<https://ir.microba.com/welcome>

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com



JOIN MICROBA’S INTERACTIVE INVESTOR HUB

Visit ir.microba.com/welcome for Microba’s interactive Investor Hub

Microba Life Sciences Ltd ABN 82 617 096 652 Level 10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621